Oral drugs that restore immune tolerance in autoimmunity
Raised to date
$7.7M
of $11M offered across 2 Form D filings
Lapix Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative oral therapeutics that restore immune system function for patients with autoimmune diseases. Through a patient-centric approach, Lapix Therapeutics is pioneering treatments that enhance the body's natural immune tolerance.
Lapix stands out by focusing on immune system restoration without broadly suppressing immunity, providing a gentler alternative to existing autoimmune therapies.
$6M equity round, first sold Aug 2024: $5.5M sold, $479K still open
$6M round, first sold Aug 2024: $5.5M sold, $479K still open
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Aug 5, 2025 | Other | $2.2M/ $5M | Form D |
| Feb 10, 2025 | Equity | $5.5M/ $6M | Form D/A |
Immune restoration drug
LPX-TI641 is an oral small-molecule drug developed to target the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is designed to restore the body’s natural immune tolerance in patients with autoimmune diseases.
Built for
Patients with autoimmune conditions
